Best Stock Reports for Berkshire Hathaway, CocaCola and Oracle
Friday, June 4, 2021
Zacks Research Daily features the best research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), The CocaCola Company (KO) and Oracle Corporation (ORCL). These research reports were handpicked from the roughly 70 reports released by our team of analysts today.
Berkshire Hathaway Stocks outperformed the Zacks Insurance – Property and Casualty sector in the last one-year period (+ 45.5% vs. + 31.4%) thanks to the financial conglomerate’s impressive investments over the years. A strong cash position supports accretive business buyouts and indicates the financial flexibility of the business.
The continued growth of the insurance business is fueling increased free float, driving earnings and generating maximum return on equity. Non-insurance activities perform better with increased revenues in recent years. A strong level of capital provides additional impetus.
However, exposure to catastrophic losses induces earnings volatility and also affects Berkshire’s property and casualty underwriting results. Huge capital expenditure remains a hindrance for the company.
Actions of Coca Cola slightly outperformed the Zacks Beverage Industry – Non-Alcoholic Beverages over the past three months (+ 9.6% vs. + 7.8%), driven by its strong surprise earnings trend that continued into Q1 2021 This is the sixth consecutive quarter of the earnings beat.
Additionally, the first row exceeded estimates after reporting a failure in the previous quarter. Additionally, revenue grew 5% year over year, while organic revenue increased 6%. The Zacks analyst believes that the company’s revenue benefited from a better price / mix ratio and increased sales of concentrates. The gains from aggressive cost management helped margins. The company is poised to take advantage of the rationalization of the portfolio and the acceleration of investments to expand its digital presence.
However, continued pressure on the out-of-home channel, which accounts for almost half of its revenues, has affected revenues. Additionally, gains in the global value share of NARTD beverages were offset by a negative channel mix.
Oracle stocks have outperformed the Zacks Computer – Software industry during the period since the start of the year (+ 25.3% versus + 8.9%). Zacks analyst believes that Oracle is benefiting from the continued momentum seen across its cloud business, through strong adoption of data cloud solutions, enterprise resource planning (ERP) offerings ) and stand-alone database.
In addition, the strong adoption of cloud-based solutions, including NetSuite ERP and Fusion ERP, bodes well. Additionally, companies like MercadoLibre, Xactly, 8×8 and Zoom Video have selected Oracle Cloud Infrastructure services, which is testament to the strength of its cloud offerings. Strong demand for the Oracle Cloud @ Customer Dedicated Region supported by ML is also expected to drive revenue. In addition, the partnership with Accenture promotes prospects.
However, increased spending on product improvement in a context of strong competition in the cloud market is likely to limit the expansion of margins.
Other noteworthy reports we feature today include Bristol-Myers Squibb Company (BMY), General Motors Company (GM) and FedEx Corporation (FDX).
5 actions in the process of doubling
Each has been selected by a Zacks expert as the # 1 favorite stock to earn + 100% or more in 2020. Each comes from a different industry and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stock in this report is flying under Wall Street’s radar, which provides a great opportunity to get into the ground floor.
Note: Sheraz Mian heads the equity research department at Zacks and is a renowned expert on aggregate earnings. He is frequently cited in print and electronic media and publishes the weekly Income trends and Income overview reports. If you would like to receive an email notification every time Sheraz publishes a new article, please click here >>>
To read of the day
According to the Zacks analyst, Northrop Grumman’s regular investments in growth projects strengthen its future prospects. However, it continues to incur higher operating expenses, which is causing concern.
The Zacks analyst believes that Southern Company’s increased regulated business customer base will support its revenue growth, but is concerned about the timing and cost overruns associated with the Vogtle project.
Rising revenue to the ground due to growth in e-commerce is boosting FedEx. At the same time, a sharp increase in operating costs is worrying.
As General Motors’ Ultium Drive system and alliances with Honda and EVgo boost its electric mobility prowess, Zacks analyst is worried about rising R&D costs and high investments by the company.
The Zacks analyst is optimistic about the stability of Integer Holdings in the cardiac, neuromodulation and advanced surgery markets.
According to Zacks analyst, the strong performance of anticoagulant drug Eliquis continues to fuel Bristol-Myers as Opdivo weakens. The approval of new drugs like Inrebic, Zeposia, among others, strengthens the portfolio.
According to the Zacks analyst, Colgate has seen price and productivity gains across all companies through its premiumization and revenue growth management initiatives, which contribute to gross margin.
According to the Zacks analyst, plans for accelerated fiber-to-the-home network deployment and buyout synergies – supported by accretive customer base – are likely to boost Altice’s margins in the long run.
According to the Zacks analyst, MasTec is poised to benefit from a strong backlog of orders and timely acquisitions. In addition, the company’s efforts to expand into the clean energy market bode well.
According to the Zacks analyst, Synovus (SNV) stock remains poised to rise, thanks to its good liquidity as well as its lucrative mergers and acquisitions. In addition, the growth in loan demand remains a positive wind.
Zacks analyst says stopping production at Emerging’s facility in Bayview as FDA investigates error that led to faulty doses of J & J’s COVID-19 vaccine is hurting short-lived prospects. term of the business.
Shorter contracts and weak hardware sales are likely to negatively impact FireEye’s performance in the short term, according to the Zacks analyst.
According to Zacks analyst, RPM sales are affected by adverse weather conditions. In addition, headwinds related to higher labor and material costs are a source of concern for the company.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.